Advanced Circulatory Systems Inc. released positive results for a clinical trial for its ResQPump and ResQPOD cardiopulmonary resuscitation assistance devices.
The Roseville, Minnesota-based CPR device developer and manufacturer said results from the study showed that the devices, when used in tandem, gave cardiac arrest victims a 53 percent better chance of survival than if they received standard CPR.
The trial, funded by the National Institutes of Health and sponsored by ACSI, compared survival rates of 813 cardiac arrest patients given CPR without the devices and 840 others treated with the assistance of the two devices, according to the company. About 5 percent of the 300,000 Americans who experience out-of-hospital cardiac arrest survive, according to University of Minnesota professor Dr. Ralph Frascone, who presented the results of the study on Nov. 14 at American Heart Association Resuscitation Science Symposium in Chicago.
Survey on the Healthcare Financial Landscape Offers a Roadmap for Stakeholders
Zelis highlights how employers, payers, and consumers are integrating digital tools to manage healthcare costs.
ACSI designed its ResQPOD to regulate airflow through a medical facemask and decreases the amount of unnecessary respiratory gas in a patient. The ResQPump was designed to help rescuers tell how much force they need to use when giving chest compressions and gives them the ability to pull the chest back up, allowing more blood to flow back in to the chest cavity.
The ResQPOD device is already approved for use in the United States. The ResQPump has not yet recevied regulatory approval fom the Food & Drug Administration and is only available outside the U.S.
Meanwhile, Deca-Medics Inc. in Columbus, Ohio, has developed a CPR device it calls the LifeBelt, which is engineered to reduce the amount of force required to perform chest compressions by half, and also promises to help users more accurately gauge the depth of those compressions.
It’s been a long, hard slog for the company, which was founded in 1994 and raised $2.5 million (including a grant from the Cleveland Clinic-led Global Cardiovascular Innovation Center) yet still doesn’t have a product on the market. Deca-Medics CEO Thom Lach is looking for $500,000 more to sustain the company during the often-bumpy process of obtaining regulatory approval to sell the device from the Food and Drug Administration.
Beyond Analytics: How Sellers Dorsey is Hard-Coding Value into Medicaid Policy [Video]
How to turn analytics into actual policy outcomes.
MedCity News contributed to this report.
The Massachusetts Medical Devices Journal is the online journal of the medical devices industry in the Commonwealth and New England, providing day-to-day coverage of the devices that save lives, the people behind them, and the burgeoning trends and developments within the industry.
This post appears through the MedCity Influencers program. Anyone can publish their perspective on business and innovation in healthcare on MedCity News through MedCity Influencers. Click here to find out how.